Search Results
Jun 04, 2026, 09:30 ET Mohegan Resorts Across North America Heat Up Summer 2026 with Hot Summer Fun
receive limited-edition Hot Summer Fun T-shirts, along with a return opportunity on Thursday for Mystery Free Slot Play prizes.Wednesdays: Dining specials are featured across participating restaurants throughout the property.Thursdays: T-shirt recipients can redeem Mystery
More news about: Mohegan
Jun 04, 2026, 09:17 ET /C O R R E C T I O N -- The Linux Foundation/
More news about: The Linux Foundation
Jun 04, 2026, 09:17 ET Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further,
More news about: Optellum
Jun 04, 2026, 09:17 ET Hycroft weist im technischen Bericht zu Spotpreisen einen Kapitalwert von 10 Milliarden US-Dollar aus und treibt die hochgradigen Silberentdeckungen Brimstone und Vortex voran
wurden nicht angewandtAlle Einheiten sind nach US-Standard Kt bedeutet 1.000 kurze Tonnen. Au- und Ag-Gehalte sind in Feinunzen pro kurze Tonne (oz/t) angegeben.Bergbau-MethodenHycroft ist als konventioneller Hartgestein-Tagebaubetrieb geplant. Der Minenplan basiert auf
More news about: Hycroft Mining Holding Corporation
Jun 04, 2026, 09:03 ET Mintz Law Firm Sponsoring Lakewood, Colorado's 2026 Rockin Block Party
p.m.Outdoor screening of "Night at the Museum" beginning at 9 p.m.Kids' activities include storytime at the Gazebo, a Q-tip T-Rex craft, a roaming T-Rex mascot, and a prize scavenger huntLocal food trucks on-site: The Rolling Stoves, The Goods Smoke and Grill, Em's Ice Cream, Kona
More news about: Mintz Law Firm
Jun 04, 2026, 08:00 ET Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting
Poster:T-35Date/Time:
More news about: Satsuma Pharmaceuticals, Inc.
Jun 04, 2026, 08:00 ET Measure Protocol Launches Predict: Agentic Cross-Platform Intelligence Built on Real Consumer Behavior
2.3TBehavioral signals
More news about: Measure Protocol
Jun 04, 2026, 08:00 ET Ramp Raises Series F at $44 Billion Valuation
Management, Insight Partners, and BroadLight Capital. Previous investors who participated are Founders Fund, Lightspeed Venture Partners, D1 Capital Partners, T. Rowe Price, General Catalyst, Alpha Wave Global, 137 Ventures, Thrive Capital, Coatue, Sands Capital, Khosla Ventures, 1789 Capital, Avenir Growth, BoxGroup,
More news about: Ramp
Jun 04, 2026, 07:45 ET Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
Foldvary-Schaefer N, Meskill GJ, Nichols DA, Steininger TL, Dai J, Measey T, Whalen M, Cairns A, Schneider LD, Bogan RK
More news about: Jazz Pharmaceuticals plc
Jun 04, 2026, 07:00 ET UMassFive and Coconut Software Deliver 13K+ Appointments with a 99.5% Completion Rate
stronger branch performance.Trusted by 200+ banks and credit unions across North America, including RBC, Mountain America Credit Union (MACU), and M&T Bank, Coconut Software helps financial institutions streamline branch traffic, optimize workforce planning, and accelerate revenue growth.Visit
More news about: Coconut Software
Jun 04, 2026, 06:59 ET Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™
Companies in the Biofertilizer MarketThe report profiles key players such as Novonesis (Denmark), UPL Limited (India), Syngenta AG (Switzerland), T. Stanes & Company (India), Lallemand Plant Care (Canada), Rizobacter (Argentina), Gujarat State Fertilizers and Chemicals Ltd (India), Madras Fertilizers
More news about: MarketsandMarkets
Jun 04, 2026, 06:00 ET CeQur® Announces Exciting Advancements: 2 Recent FDA Clearances and New Clinical Evidence to be Presented at ADA
simple, wearable devices provide freedom from multiple daily insulin injections.Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation
More news about: CeQur Corporation
Jun 04, 2026, 05:08 ET 歐洲腎臟協會大會：FLOW 試驗指出，司美格魯肽可改善糖尿病及腎病患者的生活質素
里程碑試驗結果顯示，每週用藥一次的司美格魯肽 (Semaglutide) 能顯著提升二型糖尿病 (T2D) 及慢性腎病 (CKD) 成人患者的健康相關生活質素，效果相當於每年多出約八天完全健康的時光。 試驗早前已證明，在中位數 3.4 年的治療期內，與安慰劑比較，司美格魯肽可使主要腎病事件的風險下降 24%，全因死亡率亦下降 20%。 這項新分析帶來以患者為核心的補充證據，顯示司美格魯肽的裨益不僅體現在傳統臨床指標上，更延伸至患者日常生活中的感受及機能表現。對於同時患有二型糖尿病 (T2D) 及慢性腎病 (CKD) 的患者，症狀、治療負擔以及身體機能減弱，都大大影響其日常安康，因此生活質素逐漸成為更重要的治療目標。FLOW
More news about: ERA Congress
Jun 04, 2026, 04:58 ET La bomba de calor aire-agua PHNIX R290 GreenTherm Pro ahora cuenta con la certificación TÜV SÜD RED
https://mma.prnewswire.com/media/2994117/PHNIX_R290_Air_to_Water_Heat_Pump_GreenTherm_Pro_Now_T_V_S_D_RED_Certified__with_a_SCOP_of_5_55_Veri.jpg
More news about: PHNIX
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
marketing application stage, rocbrutinib's dual covalent and non-covalent mechanism enables it to target C481-site and other resistance mutations such as T474I and L528W, providing a scientific basis for overcoming acquired resistance.The recommendation provides authoritative and standardized clinical
More news about: Lupeng Pharmaceutical Ltd
Jun 04, 2026, 02:30 ET AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren's Disease at EULAR 2026
2026.AbolerIS is currently advancing potentially first-in-class immunomodulatory antibodies targeting CD45RC, a key regulator of antigen receptor signaling in T and B cells. Data presented at EULAR 2026 show that CD45RC is highly expressed within lymphocytic infiltrates and selectively localizes to disease-affected
More news about: AbolerIS Pharma
Jun 04, 2026, 00:30 ET Gujarat becomes the New Hub in Organ Transplantation
program can also manage the full spectrum of conditions requiring transplant, such as inborn errors of immunity, bone marrow failure syndromes and CAR T-cell therapy. The packages offered are very nominal (starting from 4 lacs) compared to other bigger cities.The hospital has also been doing great
More news about: Zydus Hospitals and Healthcare Research Private Limited
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent to around eight additional days in full health per year. The trial previously demonstrated
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent to around eight additional days in full health per year. The trial previously demonstrated
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA-Kongress: Die FLOW-Studie zeigt, dass Semaglutid die Lebensqualität bei Diabetes und Nierenerkrankungen verbessert
vorgestellt wurden, zeigen, dass einmal wöchentlich verabreichtes Semaglutid die gesundheitsbezogene Lebensqualität von Erwachsenen mit Typ-2-Diabetes (T2D) und chronischer Nierenerkrankung (CKD) deutlich verbessert, was etwa acht zusätzlichen Tagen bei voller Gesundheit pro Jahr entspricht. Die
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA学術大会（ERA Congress）：FLOW試験、糖尿病と腎疾患を併存する患者におけるセマグルチドと生活の質改善との関連を示す
この試験ではこれまでに、中央値3.4年の治療期間にわたり、セマグルチドがプラセボと比較して主要な腎疾患イベントのリスクを24％、全死因死亡のリスクを20％低減することが示されています。この新たな分析は、患者中心の補完的なエビデンスを提示するものであり、セマグルチドの有益性が従来の臨床転帰にとどまらず、患者の日常生活における心身の状態や活動能力にも及ぶ可能性を示しています。T2DとCKDを併存する患者では、症状、治療負担、身体機能の低下が日々の心身の健康に大きな影響を及ぼす可能性があるため、QOLはますます重要な治療目標となっています。FLOW試験で無作為に割り付けられた3,533人の参加者のうち、1,767人がセマグルチドの投与を受け、1,766人がプラ
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congreso ERA: El ensayo FLOW muestra beneficios de la semaglutida
demuestran que la administración semanal de semaglutida mejoró significativamente la calidad de vida relacionada con la salud en adultos con diabetes tipo 2 (T2D) y enfermedad renal crónica (ERC), lo que equivale a aproximadamente ocho días adicionales de plena salud al año. El ensayo ya había demostrado
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA 총회: FLOW 임상시험, 세마글루타이드가 당뇨병 및 신장 질환 환자의 삶의 질 개선과 관련 있음을 보여줘
24%, 모든 원인에 의한 사망률을 20% 감소시킨다는 사실을 입증한 바 있다. 이번 새로운 분석은 환자 중심의 보완적 근거를 제시하며, 세마글루타이드의 이점이 전통적인 임상 결과를 넘어 환자가 일상생활에서 느끼고 기능하는 방식까지 확장될 수 있음을 보여준다.T2D와 CKD를 모두 앓는 사람들에게는 증상, 치료 부담, 신체 기능 저하가 일상적인 웰빙에 상당한 영향을 미칠 수 있어 삶의 질이 점점 더 중요한 치료 목표가 되고 있다.FLOW 임상시험에 무작위 배정된 참가자 3533명 중 1767명은 세마글루타이드를,
More news about: ERA Congress